Brokerages Set Hologic, Inc. (NASDAQ:HOLX) PT at $78.42

Hologic, Inc. (NASDAQ:HOLX) has been given a consensus recommendation of “Hold” by the fifteen research firms that are presently covering the company, MarketBeat.com reports. Thirteen analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $78.4167.

A number of analysts have recently commented on HOLX shares. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Morgan Stanley boosted their target price on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a report on Friday, November 21st. Finally, Evercore cut Hologic from an “outperform” rating to an “in-line” rating and lowered their price objective for the stock from $79.00 to $78.00 in a research report on Monday, January 5th.

Institutional Investors Weigh In On Hologic

Several institutional investors and hedge funds have recently added to or reduced their stakes in HOLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Hologic by 10.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock valued at $2,395,000 after purchasing an additional 3,520 shares in the last quarter. Empowered Funds LLC lifted its stake in Hologic by 27.7% in the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock valued at $1,081,000 after purchasing an additional 3,790 shares during the last quarter. Ethic Inc. boosted its position in Hologic by 127.5% in the second quarter. Ethic Inc. now owns 10,200 shares of the medical equipment provider’s stock valued at $663,000 after buying an additional 5,717 shares in the last quarter. Carnegie Investment Counsel grew its stake in shares of Hologic by 10.6% during the second quarter. Carnegie Investment Counsel now owns 221,528 shares of the medical equipment provider’s stock worth $14,435,000 after buying an additional 21,273 shares during the last quarter. Finally, AlTi Global Inc. grew its stake in shares of Hologic by 27.9% during the second quarter. AlTi Global Inc. now owns 14,974 shares of the medical equipment provider’s stock worth $986,000 after buying an additional 3,266 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

Hologic stock opened at $75.43 on Friday. Hologic has a 12-month low of $51.90 and a 12-month high of $75.47. The stock has a 50-day simple moving average of $74.92 and a 200 day simple moving average of $71.91. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $16.84 billion, a price-to-earnings ratio of 31.43, a P/E/G ratio of 2.25 and a beta of 0.72.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period last year, the business posted $0.87 EPS. On average, research analysts anticipate that Hologic will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.